Nuvilex Announces the Opening of Austrianova’s cGMP Live Cell Encapsulation Facility in Thailand
December 04 2014 - 9:30AM
InvestorsHub NewsWire
SILVER SPRING, MD -
December 4, 2014 - InvestorsHub NewsWire - Nuvilex, Inc. (OTCQB:
NVLX), a clinical-stage biotechnology company providing cell
therapy solutions for the treatment of diseases, announced today
that Nuvilex executives joined Thailand government officials at the
grand opening of Austrianova’s current Good Manufacturing Practices
(cGMP) live-cell encapsulation facility within the Thai Science
Park (TSP) in Bangkok, Thailand. The TSP is the premier Science,
Technology and Innovation hub of Thailand and home to many leading
international hi-tech and bio-tech companies.
Nuvilex contracted with its partner Austrianova to establish the
manufacturing facility that will produce the
Cell-in-a-Box® live-cell encapsulation product
containing cancer prodrug-activating cells that will be used for
the Phase 2b clinical trial of Nuvilex's pancreatic cancer
treatment in Australia and for clinical trials in the United States
related to the intractable pain associated with pancreatic cancer
and the accumulation of malignant ascites fluid that results from
late-stage pancreatic cancer and other abdominal cancers. This
facility will also be used to encapsulate insulin-producing cells
that will be pivotal for clinical trials of Nuvilex’s treatment for
insulin-dependent diabetes.
Nuvilex CEO and President, Kenneth L. Waggoner, stated, “Nuvilex is
pleased that the new cGMP facility that will perform live cell
encapsulation using the Cell-in-a-Box® encapsulation
technology is officially open in Thailand. This is a vitally
important event on the path to the new and later stage clinical
trials for Nuvilex. We are pleased to have been invited as guest of
honor at the grand opening ceremony and to have met with so many
scientists and professors involved with the
Cell-in-a-Box® technology.”
Dr. Brian Salmons, CEO and President of Austrianova, commented, “We
are proud to have opened our unique cGMP facility which utilizes
the first state-of-the-art, custom-built, controlled gaseous
environment isolator based cell production system in Asia. This
isolator system, housed in a newly built conventional Class D
cleanroom, will ensure that all Cell-in-a-Box® products
are manufactured to the highest international pharmaceutical
production standards.”
Prof. Walter H. Günzburg, Chief Scientific Officer of Nuvilex and
Chairman of Austrianova, said, “Together with Thailand Center of
Excellence in Life Sciences, we have worked for over a year to
develop this world-first encapsulated cell production capability.
Finally, through the close collaborative efforts of this Thai
Government Agency with Austrianova and the Thailand Science Park,
we have been able to achieve, in a remarkably short period, the
realization of this unique facility.”
To view pictures of the
event and the new facility in the Thai Science Park,
visit:
http://www.nuvilex.com/index.php?option=com_eventgallery&view=event&layout=tiles&folder=Event1&Itemid=133
About
Nuvilex
Nuvilex (OTCQB:
NVLX) is a clinical stage biotechnology company focused on
developing and preparing to commercialize treatments for cancer and
diabetes based upon a proprietary cellulose-based live cell
encapsulation technology known as Cell-in-a-Box®. This
unique and patented technology will be used as a platform upon
which treatments for several types of cancer, including advanced,
inoperable pancreatic cancer, and diabetes are being built.
Nuvilex's treatment for pancreatic cancer involves the well-known
anticancer prodrug ifosfamide, together with encapsulated live
cells, which convert ifosfamide into its active or "cancer-killing"
form. Nuvilex is also working towards improving the quality of life
for patients with advanced pancreatic cancer and on treatments for
other types of solid cancerous tumors. In addition, Nuvilex is
developing treatments for cancers based upon cannabinoid-like drugs
by examining ways to exploit the benefits of the
Cell-in-a-Box® technology in optimizing the anticancer
effectiveness of such drugs while minimizing or outright
eliminating the debilitating side effects usually associated with
cancer treatments. This provides Nuvilex a unique opportunity to
develop “green” approaches to fighting cancers, such as those of
the pancreas, brain and breast, which affect hundreds of thousands
of individuals worldwide every year.
Safe
Harbor
This press release may
contain forward-looking statements regarding Nuvilex and its future
events and results that involve inherent risks and uncertainties.
The words "anticipate," "believe," "estimate," "expect," "intend,"
"plan" and similar expressions, as they relate to Nuvilex or its
management, are intended to identify forward-looking statements.
Important factors, many of which are beyond the control of Nuvilex,
that could cause actual results to differ materially from those set
forth in the forward-looking statements include Nuvilex's ability
to continue as a going concern, delays or unsuccessful results in
clinical trials or flaws or defects regarding its product
candidates, changes in relevant legislation or regulatory
requirements, uncertainty of protection of Nuvilex's intellectual
property and Nuvilex's continued ability to raise capital. Nuvilex
does not assume any obligation to update any of these
forward-looking statements.
More information about Nuvilex can be found at www.nuvilex.com. It can also be obtained by contacting
Investor Relations.
Investor Relations Contacts:
Clare Matschullat
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 106
cmatschullat@bplifescience.com